Filing summary
Identity and period: The supplied metadata identifies Solana Co., but the filing itself is Helius Medical Technologies, Inc. (Form 10-Q; CIK/company details are not provided here), for the quarter ended September 30, 2015. The six-month period began April 1, 2015. This is a material source/metadata mismatch. The company develops the PoNS neuromodulation device and had not generated commercial revenue.
Financial results and position
| Metric | Three months ended September 30, 2015 | Six months ended September 30, 2015 |
|---|---|---|
| Commercial revenue | None | None |
| Operating expenses | $1.062 million | $3.897 million |
| Operating loss | $1.062 million | $3.897 million |
| Net income (loss) | $1.039 million | $(2.055) million |
| Net income (loss) per share | $0.02 | $(0.03) |
- Quarterly net income was driven by noncash gains: $1.484 million from revaluation of derivative liabilities and $589,000 in foreign-exchange gains. These items do not reflect operating profitability.
- Six-month operating cash use was $3.394 million, versus $2.759 million in the prior-year period. Financing provided $2.931 million, principally from equity placements and a $200,000 promissory note; investing provided $378,000. Cash at September 30 was $192,256.
- At September 30, current assets were $719,108 and current liabilities were $1,461,751, for a working-capital deficit of approximately $742,643. The filing’s balance-sheet table has apparent column-order inconsistencies; these figures are stated in MD&A. The company reported total assets of $719,108 and a capital deficit of $1.105 million.
- The $200,000 note bore 6% interest and was due six months after issuance; it was repaid on October 28, 2015, with 30,000 shares also issued to the lender. The derivative liability was reported at $361,909 at September 30.
Changes versus prior comparable periods
- Six-month net loss narrowed from $4.916 million in 2014 to $2.055 million in 2015, while operating expenses increased from $3.743 million to $3.897 million. Non-operating gains, including derivative revaluation and foreign exchange, substantially affected the comparison.
- Six-month research and development expense declined to $1.630 million from $1.716 million; quarterly R&D fell to $243,262 from $1.063 million. Management attributed the decline to a deceleration in development and trial-preparation activity.
- Six-month advertising, marketing and investor-relations expense increased to $548,581 from $404,182; wages and salaries increased to $662,414 from $465,998. Cash used in operations increased year over year, and cash fell from $418,893 at March 31 to $192,256 at September 30.
- The company raised gross proceeds of approximately $2.818 million through three private placements during the six months, issuing shares and warrants.
Outlook, risks and notable items
- Going concern: Management said available resources were insufficient for the ensuing fiscal year and, without additional financing, insufficient through the third quarter of 2016. The filing cites substantial doubt about the company’s ability to continue as a going concern. It expects continued operating losses and cash outflows and may need to raise debt or equity; financing availability and terms are uncertain.
- Generating revenue depends on completing device development, obtaining regulatory clearance, manufacturing a commercially viable product and generating customer demand. The filing provides no quantified revenue or earnings guidance.
- After quarter-end, A&B Company Limited agreed to fund up to $7 million and to develop and commercialize PoNS in specified Asian territories. The first $2 million was drawn and, on November 10, 2015, settled through approximately 2.083 million shares at $0.96 and 1.042 million three-year warrants at $1.44. The remaining $5 million was optional, available for drawdown within six months subject to the agreement’s terms. A&B also assumed specified regional development and regulatory costs; the company may receive handling fees and a milestone payment.
- On November 2, 2015, the company announced positive results from an MS pilot study; the filing says the study was intended to inform future study design and marketing-authorization requests.
- A lawsuit seeks damages exceeding $225,000 over alleged consulting-agreement breaches and use of business and marketing plans. Management estimated the contingent liability as immaterial but said the outcome could not be determined.
- Disclosure controls and procedures were ineffective as of September 30 due to a material weakness involving insufficient technical accounting expertise. Remediation was in progress.
- Management reported no material changes to the risk factors in its March 31, 2015 Form 10-K. Foreign-exchange exposure remains; the company had no currency hedges.
Investor verification priorities
- Confirm the filing issuer and reporting period: the submitted metadata says Solana Co., while the filing is for Helius Medical Technologies, Inc.
- Reconcile the apparent balance-sheet column-order inconsistency against the filed statements, particularly the September 30 cash and current-asset figures.
- Assess the company’s financing runway, the terms and availability of A&B’s remaining $5 million commitment, and any dilution from shares and warrants.
- Separate recurring operating performance from noncash derivative and foreign-exchange gains; evaluate the cash burn and lack of commercial revenue.
- Track PoNS development, clinical evidence and regulatory milestones, the disclosed lawsuit, and remediation of the material weakness in disclosure controls.